Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Enalapril 4mg/5ml oral liquid
0205051I0AAAZAZ
|
Enalapril maleate | Enalapril maleate | Cardiovascular System | No data available |
|
Enalapril 500micrograms/5ml oral liquid
0205051I0AAAVAV
|
Enalapril maleate | Enalapril maleate | Cardiovascular System | No data available |
|
Enalapril 600micrograms/5ml oral liquid
0205051I0AAARAR
|
Enalapril maleate | Enalapril maleate | Cardiovascular System | No data available |
|
Enalapril 7.5mg/5ml oral liquid
0205051I0AABWBW
|
Enalapril maleate | Enalapril maleate | Cardiovascular System | No data available |
|
Enalapril 7mg/5ml oral liquid
0205051I0AABCBC
|
Enalapril maleate | Enalapril maleate | Cardiovascular System | No data available |
|
Enalapril 8mg/5ml oral liquid
0205051I0AABQBQ
|
Enalapril maleate | Enalapril maleate | Cardiovascular System | No data available |
|
Enalto 10mg orodispersible tablets
0403030X0BCABAH
|
Enalto | Escitalopram | Central Nervous System | No data available |
|
Enalto 15mg orodispersible tablets
0403030X0BCACAI
|
Enalto | Escitalopram | Central Nervous System | No data available |
|
Enalto 20mg orodispersible tablets
0403030X0BCADAJ
|
Enalto | Escitalopram | Central Nervous System | No data available |
|
Enalto 5mg orodispersible tablets
0403030X0BCAAAG
|
Enalto | Escitalopram | Central Nervous System | No data available |
|
Enbrel 25mg inj vials
1001030D0BBAAAA
|
Enbrel | Etanercept | Musculoskeletal and Joint Diseases | No data available |
|
Enbrel 25mg/0.5ml inj pre-filled MyClic pens
1001030D0BBAHAG
|
Enbrel | Etanercept | Musculoskeletal and Joint Diseases | No data available |
|
Enbrel 25mg/0.5ml solution for injection pre-filled syringes
1001030D0BBAEAD
|
Enbrel | Etanercept | Musculoskeletal and Joint Diseases | No data available |
|
Enbrel 50mg inj vials
1001030D0BBABAB
|
Enbrel | Etanercept | Musculoskeletal and Joint Diseases | No data available |
|
Enbrel 50mg/1ml solution for injection pre-filled syringes
1001030D0BBACAC
|
Enbrel | Etanercept | Musculoskeletal and Joint Diseases | No data available |
|
Enbrel Paediatric 10mg inj vials
1001030D0BBAGAF
|
Enbrel | Etanercept | Musculoskeletal and Joint Diseases | No data available |
|
Enbrel Paediatric 25mg inj vials
1001030D0BBADAA
|
Enbrel | Etanercept | Musculoskeletal and Joint Diseases | No data available |
|
Encorafenib 50mg capsules
0801050CMAAABAB
|
Encorafenib | Encorafenib | Malignant Disease and Immunosuppression | No data available |
|
Encorafenib 75mg capsules
0801050CMAAAAAA
|
Encorafenib | Encorafenib | Malignant Disease and Immunosuppression | No data available |
|
Endekay 0.05% fluoride mouthrinse alcohol free
0905030G0BCAGBC
|
Endekay | Sodium fluoride | Nutrition and Blood | No data available |
|
Endekay Fluorinse 2% mouthwash
0905030G0BCAEBE
|
Endekay | Sodium fluoride | Nutrition and Blood | No data available |
|
Endekay Fluotabs 3-6 Years 1.1mg tablets
0905030G0BCABAR
|
Endekay | Sodium fluoride | Nutrition and Blood | No data available |
|
Endekay Fluotabs 6+ Years 2.2mg tablets
0905030G0BCACAT
|
Endekay | Sodium fluoride | Nutrition and Blood | No data available |
|
Endoxana 1g powder for solution for injection vials
0801010H0BBAFAD
|
Endoxana | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Endoxana 200mg powder for solution for injection vials
0801010H0BBADAB
|
Endoxana | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.